BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

670 related articles for article (PubMed ID: 26330336)

  • 1. Toward Personalized Medicine: Using Cardiomyocytes Differentiated From Urine-Derived Pluripotent Stem Cells to Recapitulate Electrophysiological Characteristics of Type 2 Long QT Syndrome.
    Jouni M; Si-Tayeb K; Es-Salah-Lamoureux Z; Latypova X; Champon B; Caillaud A; Rungoat A; Charpentier F; Loussouarn G; Baró I; Zibara K; Lemarchand P; Gaborit N
    J Am Heart Assoc; 2015 Sep; 4(9):e002159. PubMed ID: 26330336
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modelling the long QT syndrome with induced pluripotent stem cells.
    Itzhaki I; Maizels L; Huber I; Zwi-Dantsis L; Caspi O; Winterstern A; Feldman O; Gepstein A; Arbel G; Hammerman H; Boulos M; Gepstein L
    Nature; 2011 Mar; 471(7337):225-9. PubMed ID: 21240260
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Re-trafficking of hERG reverses long QT syndrome 2 phenotype in human iPS-derived cardiomyocytes.
    Mehta A; Sequiera GL; Ramachandra CJ; Sudibyo Y; Chung Y; Sheng J; Wong KY; Tan TH; Wong P; Liew R; Shim W
    Cardiovasc Res; 2014 Jun; 102(3):497-506. PubMed ID: 24623279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eag Domains Regulate LQT Mutant hERG Channels in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes.
    Liu QN; Trudeau MC
    PLoS One; 2015; 10(4):e0123951. PubMed ID: 25923442
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modeling Short QT Syndrome Using Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes.
    El-Battrawy I; Lan H; Cyganek L; Zhao Z; Li X; Buljubasic F; Lang S; Yücel G; Sattler K; Zimmermann WH; Utikal J; Wieland T; Ravens U; Borggrefe M; Zhou XB; Akin I
    J Am Heart Assoc; 2018 Mar; 7(7):. PubMed ID: 29574456
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patient-Specific and Gene-Corrected Induced Pluripotent Stem Cell-Derived Cardiomyocytes Elucidate Single-Cell Phenotype of Short QT Syndrome.
    Guo F; Sun Y; Wang X; Wang H; Wang J; Gong T; Chen X; Zhang P; Su L; Fu G; Su J; Yang S; Lai R; Jiang C; Liang P
    Circ Res; 2019 Jan; 124(1):66-78. PubMed ID: 30582453
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Isogenic human pluripotent stem cell pairs reveal the role of a KCNH2 mutation in long-QT syndrome.
    Bellin M; Casini S; Davis RP; D'Aniello C; Haas J; Ward-van Oostwaard D; Tertoolen LG; Jung CB; Elliott DA; Welling A; Laugwitz KL; Moretti A; Mummery CL
    EMBO J; 2013 Dec; 32(24):3161-75. PubMed ID: 24213244
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Model for long QT syndrome type 2 using human iPS cells demonstrates arrhythmogenic characteristics in cell culture.
    Lahti AL; Kujala VJ; Chapman H; Koivisto AP; Pekkanen-Mattila M; Kerkelä E; Hyttinen J; Kontula K; Swan H; Conklin BR; Yamanaka S; Silvennoinen O; Aalto-Setälä K
    Dis Model Mech; 2012 Mar; 5(2):220-30. PubMed ID: 22052944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The KCNH2-IVS9-28A/G mutation causes aberrant isoform expression and hERG trafficking defect in cardiomyocytes derived from patients affected by Long QT Syndrome type 2.
    Mura M; Mehta A; Ramachandra CJ; Zappatore R; Pisano F; Ciuffreda MC; Barbaccia V; Crotti L; Schwartz PJ; Shim W; Gnecchi M
    Int J Cardiol; 2017 Aug; 240():367-371. PubMed ID: 28433559
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tbx20 controls the expression of the KCNH2 gene and of hERG channels.
    Caballero R; Utrilla RG; Amorós I; Matamoros M; Pérez-Hernández M; Tinaquero D; Alfayate S; Nieto-Marín P; Guerrero-Serna G; Liu QH; Ramos-Mondragón R; Ponce-Balbuena D; Herron T; Campbell KF; Filgueiras-Rama D; Peinado R; López-Sendón JL; Jalife J; Delpón E; Tamargo J
    Proc Natl Acad Sci U S A; 2017 Jan; 114(3):E416-E425. PubMed ID: 28049825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional Impact of BeKm-1, a High-Affinity hERG Blocker, on Cardiomyocytes Derived from Human-Induced Pluripotent Stem Cells.
    De Waard S; Montnach J; Ribeiro B; Nicolas S; Forest V; Charpentier F; Mangoni ME; Gaborit N; Ronjat M; Loussouarn G; Lemarchand P; De Waard M
    Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 32998413
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug screening using a library of human induced pluripotent stem cell-derived cardiomyocytes reveals disease-specific patterns of cardiotoxicity.
    Liang P; Lan F; Lee AS; Gong T; Sanchez-Freire V; Wang Y; Diecke S; Sallam K; Knowles JW; Wang PJ; Nguyen PK; Bers DM; Robbins RC; Wu JC
    Circulation; 2013 Apr; 127(16):1677-91. PubMed ID: 23519760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disruption of protein quality control of the human ether-à-go-go related gene K
    Ledford HA; Ren L; Thai PN; Park S; Timofeyev V; Sirish P; Xu W; Emigh AM; Priest JR; Perez MV; Ashley EA; Yarov-Yarovoy V; Yamoah EN; Zhang XD; Chiamvimonvat N
    Heart Rhythm; 2022 Feb; 19(2):281-292. PubMed ID: 34634443
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Promise and Potential Peril With Lumacaftor for the Trafficking Defective Type 2 Long-QT Syndrome-Causative Variants, p.G604S, p.N633S, and p.R685P, Using Patient-Specific Re-Engineered Cardiomyocytes.
    O'Hare BJ; John Kim CS; Hamrick SK; Ye D; Tester DJ; Ackerman MJ
    Circ Genom Precis Med; 2020 Oct; 13(5):466-475. PubMed ID: 32940533
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug-Mediated Shortening of Action Potentials in LQTS2 Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes.
    Duncan G; Firth K; George V; Hoang MD; Staniforth A; Smith G; Denning C
    Stem Cells Dev; 2017 Dec; 26(23):1695-1705. PubMed ID: 28992755
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modeling Reentry in the Short QT Syndrome With Human-Induced Pluripotent Stem Cell-Derived Cardiac Cell Sheets.
    Shinnawi R; Shaheen N; Huber I; Shiti A; Arbel G; Gepstein A; Ballan N; Setter N; Tijsen AJ; Borggrefe M; Gepstein L
    J Am Coll Cardiol; 2019 May; 73(18):2310-2324. PubMed ID: 31072576
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mouse ERG K(+) channel clones reveal differences in protein trafficking and function.
    Lin EC; Moungey BM; Lim E; Concannon SP; Anderson CL; Kyle JW; Makielski JC; Balijepalli SY; January CT
    J Am Heart Assoc; 2014 Dec; 3(6):e001491. PubMed ID: 25497881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Large-Scale Simulation of the Phenotypical Variability Induced by Loss-of-Function Long QT Mutations in Human Induced Pluripotent Stem Cell Cardiomyocytes.
    Paci M; Casini S; Bellin M; Hyttinen J; Severi S
    Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30428582
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of the CACNA1C-R518C Missense Mutation in the Pathobiology of Long-QT Syndrome Using Human Induced Pluripotent Stem Cell Cardiomyocytes Shows Action Potential Prolongation and L-Type Calcium Channel Perturbation.
    Estes SI; Ye D; Zhou W; Dotzler SM; Tester DJ; Bos JM; Kim CSJ; Ackerman MJ
    Circ Genom Precis Med; 2019 Aug; 12(8):e002534. PubMed ID: 31430211
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug evaluation in cardiomyocytes derived from human induced pluripotent stem cells carrying a long QT syndrome type 2 mutation.
    Matsa E; Rajamohan D; Dick E; Young L; Mellor I; Staniforth A; Denning C
    Eur Heart J; 2011 Apr; 32(8):952-62. PubMed ID: 21367833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.